Case 18
|
60-yr male |
liver, kidney |
0.6 |
Pleural
effusion |
Plasmablastic |
Negative |
HHV8-, CD20-, CD79a-, pax5-,
CD30-, cd3-, mum1+, CYTOPLASMIC Lambda restricted |
MYC-rearranged |
Monomorphic PTLD with PBL feature |
Reduced immunosuppressive |
Died of
disease in 2 weeks |
Case 229
|
63-yr male |
liver |
11 |
Ascites,
splenomegaly |
Plasmablastic |
Positive |
PAX5+, MUM1+, CD20-, CD79a-,
CD30-, CD45-, HHV8- |
MYC-rearranged |
Monomorphic PTLD with PBL feature |
N/A |
N/A |
Case 331
|
57-yr male |
liver |
2.0 |
Pleural effusion |
Large tumor cells |
Positive |
CD20-, CD79a+, kappa restricted, CD3-,
CD56-, HHV8- |
N/A |
Monomorphic PTLD with PBL feature |
N/A |
Died of
disease in 3 months |
Case 411
|
12-yr-female |
heart |
10 |
Small
intestine, pleura |
Plasmablastic |
Negative |
CD20-, PAX5-, CD79a+,
CD19 partial+, CD138+ |
MYC-rearranged |
Monomorphic PTLD with PBL
feature |
Surgery, and chemotherapy |
In remission at
15-years-followup |
Case 511
|
15-yr-male |
heart |
10 |
Small intestine |
Plasmablastic |
Negative |
CD20 rare+, CD19+, PAX5+, CD138 partial+,
CD79a partial+, HHV8- |
MYC-rearranged |
Monomorphic PTLD with PBL
feature |
Chemotherapy (Bortezomib-EPOCH); ASCT |
In remission at
6-years-followup |
Case 614
|
22-yr-female |
kidney |
17 |
Small
intestine |
Large tumor cells |
Negative |
1st tumor: CD20+, PAX5+,
cytoCD3+, CD30-, CD138-, Ki67>90%, HHV8-, EBV-;
2nd tumor: CD20-, PAX5-, cytoCD3+, CD138+, CD30-,
Ki67>90%, HHV8- |
Polyclonal TCR; Monoclonal IgH |
1st
tumor: DLBCL; 2nd tumor: PBL, monomorphic PTLD |
Chemotherapy; ASCT |
Died of disease in 7 months |